[The relationship between hyperuricaemia and clinic pathology of IgA nephropathy]

To analyze the correlation between the level of serum uric acid and the clinical and pathological features of IgA nephropathy.

Totally 148 patients diagnosed as IgA nephropathy by renal biopsy in our hospital from January 2007 to December 2010 were divided into hyperuricaemic group (41 cases) and non-hyperuricaemic group (107 cases) according to the level of serum uric acid. The clinical parameters and renal pathology grade were compared.

There were significant differences between hyperuricaemic group and non-hyperuricaemic group in the incidences of hypertension (63.4% vs 38.3%), disease duration [(18.90 ± 10.12) months vs (9.46 ± 3.91) months] and body mass index [(22.81 ± 3.60) kg/m(2) vs (15.32 ± 2.54) kg/m(2)] (all P < 0.05), while no differences in age and sex (both P > 0.05). The blood urea nitrogen (BUN) [(8.93 ± 4.28) mmol/L vs (5.21 ± 2.18) mmol/L], creatinine (Cr) [(155.96 ± 107.72) µmol/L vs (79.52 ± 40.01) µmol/L], serum triglycerides [(2.11 ± 1.06) mmol/L vs (1.86 ± 1.20) mmol/L] and 24-hour urine protein amount [(4328.16 ± 1434.25) mg/24 h vs (2885.10 ± 1388.15) mg/24 h] were significantly different between the two groups (all P < 0.05). The percentage of Lee's grade I + II in hyperuricaemic group was 12.2%, and IV + V grade was 39.0%, while percentage of Lee's grade I + II in non-hyperuricaemic group was 25.2%, and IV + V grade was 16.9% (P < 0.05). Tubulointerstitial lesions (TIL) grade III + IV was more in hyperuricaemic group, which was 68.3%, while TIL grade II was more in non-hyperuricaemic group, which was 76.6%. Renal artery damage grade II + III was more in hyperuricaemic group, which was 73.2%, while renal artery damage grade 0 + I was more in non-hyperuricaemic group, which was 69.2%.

The level of serum uric acid was related with 24-hour urine protein amount, blood pressure and kidney function in IgA nephropathy, and Lee's grade, TIL grade and renal artery damage grade were severe in hyperuricaemic group.